COMMUNIQUÉS West-GlobeNewswire

Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer
27/05/2025
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual [...]
Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer
27/05/2025
Ms. Kline to lead Palvella’s commercial buildout for planned standalone U.S. launch of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations, a serious, rare, and lifelong [...]
DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal
27/05/2025
DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView ® System, which uses multi-spectral imaging and AI algorithms to [...]
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
27/05/2025
- Study will assess relative efficacy, safety, and immunogenicity of Vaxart’s oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE [...]
Emory Healthcare Researchers Use Dynamic Digital Radiography to Compare Shoulder Improvement of Two Surgical Interventions for Massive Irreparable Rotator Cuff Tears
27/05/2025
WAYNE, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., congratulates Emory Healthcare researchers on the publication of a new study using Dynamic Digital Radiography (DDR) to compare [...]
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
27/05/2025
CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
27/05/2025
SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the [...]
ORYZON to Provide Corporate Progress Updates at Several Events in May-June
27/05/2025
Foro MedCap 2025 BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical- [...]
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
27/05/2025
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post- [...]
Hydreight Launches Personalized Genetic Testing and Wellness Solution on VSDHOne Platform
27/05/2025
Expands access to precision-based care through at-home DNA testing and personalized health plans VANCOUVER, British Columbia and LAS VEGAS, May 27, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or [...]
Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
27/05/2025
Novel combination with efti has met the trial’s primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcoma Detailed results are planned for presentation [...]
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
27/05/2025
NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Salvia BioElectronics Secures $60M in Oversubscribed Series B to Bring its Pioneering Migraine Therapy to Market
27/05/2025
Series B funding round led by Innovation Industries, with participation from Invest-NL, EIC Fund, and existing investors Inkef, Panakès Partners, SHS Capital, Dolby Family Ventures, Brabant Development Agency (BOM) and [...]
C4X Discovery receives latest milestone payment from Sanofi
27/05/2025
€8 million milestone payment triggered by pre-clinical progression in oral IL-17A inhibitor programme 27 May 2025 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces that it has [...]
dacadoo Launches Generation 5 of Its Award-Winning Digital Health Engagement Platform
27/05/2025
Zurich, CH, May 27, 2025 (GLOBE NEWSWIRE) -- dacadoo, a global leader in digital health engagement technology since 2010 with over 100 granted patents, announces the launch of Generation 5 of its Digital Health [...]
Epitopea annonce un article dans Nature Cancer sur de nouvelles cibles d'immunothérapie dans le mélanome et le cancer du poumon non à petites cellules (NSCLC)
27/05/2025
Validation supplémentaire des Cryptigens™ en tant que cibles exploitables pour l'immunothérapie du cancer MONTRÉAL et CAMBRIDGE, Royaume-Uni, 27 mai 2025 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique [...]
Epitopea Announces Nature Cancer Paper on Novel Immunotherapy Targets in Melanoma and NSCLC
27/05/2025
Further Validates Cryptigens™ as Actionable Targets for Cancer Immunotherapy MONTREAL and CAMBRIDGE, United Kingdom, May 27, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapy company, and Institute [...]
ITM Secures Up to $262.5m in Non-dilutive Debt Financing with Blue Owl Managed Funds
27/05/2025
Debt capital to support commercial readiness and potential U.S. launch of n.c.a. 177 Lu-edotreotide (ITM-11), following positive Phase 3 results Flexible funding structure enables continued advancement of ITM’s targeted [...]
Communiqué de presse : Sanofi finalise l’acquisition du DR-0201
27/05/2025
Sanofi finalise l’acquisition du DR-0201 Paris, le 27 mars 2025. Sanofi annonce la finalisation de l’acquisition du DR-0201, un anticorps bispécifique ciblé qui engage les cellules myéloïdes, à Dren Bio, Inc., société [...]

Pages